Formulations, procedures, methods and combinations thereof for reducing or preventing the development, or the risk of development, of neuropathology as a result of trauma

A method for the prevention of, for reducing the effects of, or for reducing the risk of development of neuropathology incident to trauma, the method comprising the steps or actions of

• A. providing a formulation adapted for the prevention of the development of neuropathology, wherein the formulation comprises four biologically active compounds in amounts that are pharmaceutically effective for each compound, respectively, when administered in combination with the other three biologically active compounds, the four compounds comprising a pharmaceutically effective amount of:
• i. at least one biologically active compound from the group comprising anticonvulsants;
• ii. at least one biologically active compound from the group comprising neurosteroids;
• iii. at least one biologically active compound from the group comprising NK-1 receptor antagonists;
• and
• iv. at least one biologically active compound from the group comprising lithium-containing compounds,
• wherein the formulation is in a form adapted and arranged for administration to a mammal in need thereof, such that the development, or the risk of development, of neuropathology is reduced, lessened, attenuated or prevented, and
• B. administering the formulation to a mammal in need thereof.

A formulation adapted for the prevention of the development of neuropathology, or for the amelioration of the effects caused by trauma to a subject, the formulation comprising any two, any three or all four biologically active compounds in amounts that are pharmaceutically effective for each compound, respectively, when administered in combination with the other biologically active compounds, the two or three or four compounds comprising a pharmaceutically effective amount of:

• A. at least one biologically active compound from the group comprising anticonvulsants and antiepileptics, wherein the compound is one or more of gabapentin, pregabalin and valproic acid,
• B. at least one biologically active compound from the group comprising neurosteroids, neuroactive steroids and progestins, wherein the compound is one or more of megestrol acetate, ganaxolone and methylprednisolone,
• C. at least one biologically active compound from the group comprising NK-1 receptor antagonists, wherein the compound is one or more of aprepitant, vestipitant and casopitant, and
• D. at least one biologically active compound from the group comprising lithium-containing compounds, wherein the lithium-containing compound is one or more of lithium carbonate, lithium citrate and lithium chloride,
• wherein the formulation is in a form and a dosage with respect to each of its components such that it is adapted and arranged for administration to a mammal in need thereof, such that the development, or the risk of development, of neuropathology is reduced, lessened, attenuated or prevented.